Další formáty:
BibTeX
LaTeX
RIS
@article{1386067,
author = {Horská, Kateřina and Rudá, Jana and Dražanová, Eva and Karpisek, Michal and Demlová, Regina and Kašpárek, Tomáš and Kotolová, Hana},
article_location = {Oxford},
article_number = {1 September 2017},
doi = {http://dx.doi.org/10.1016/j.neuropharm.2017.06.003},
keywords = {Adipokine; Aripiprazole; Leptin; Lipid profile; PolyI:C; Schizophrenia Wistar rats},
language = {eng},
issn = {0028-3908},
journal = {Neuropharmacology},
title = {Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats},
url = {https://www.sciencedirect.com/science/article/pii/S0028390817302733?via%3Dihub},
volume = {123},
year = {2017}
}
TY - JOUR
ID - 1386067
AU - Horská, Kateřina - Rudá, Jana - Dražanová, Eva - Karpisek, Michal - Demlová, Regina - Kašpárek, Tomáš - Kotolová, Hana
PY - 2017
TI - Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats
JF - Neuropharmacology
VL - 123
IS - 1 September 2017
SP - 148-158
EP - 148-158
PB - Pergamon-Elsevier Science LTD
SN - 00283908
KW - Adipokine
KW - Aripiprazole
KW - Leptin
KW - Lipid profile
KW - PolyI:C
KW - Schizophrenia Wistar rats
UR - https://www.sciencedirect.com/science/article/pii/S0028390817302733?via%3Dihub
L2 - https://www.sciencedirect.com/science/article/pii/S0028390817302733?via%3Dihub
N2 - Schizophrenia appears to be linked to higher incidence of metabolic syndrome even in the absence of antipsychotic treatment. Atypical antipsychotics substantially differ in their propensity to induce metabolic alterations. Aripiprazole is considered to represent an antipsychotic drug with low risk of metabolic syndrome development. The aim of this study was to evaluate metabolic phenotype of neurodevelopmental polyI:C rat model and assess metabolic effects of chronic aripiprazole treatment with regard to complex neuroendocrine regulations of energy homeostasis. Polyinosinic:polycytidylic acid (polyI:C) was administered subcutaneously at a dose of 8 mg/kg in 10 ml on gestational day 15 to female Wistar rats. For this study 20 polyI:C and 20 control adult male offspring were used, randomly divided into 2 groups per 10 animals for chronic aripiprazole treatment and vehicle. Aripiprazole (5 mg/kg, dissolved tablets, ABILIFY®) was administered once daily via oral gavage for a month. Altered lipid profile in polyI:C model was observed and a trend towards different dynamics of weight gain in polyI:C rats was noted in the absence of significant antipsychotic treatment effect. PolyI:C model was not associated with changes in other parameters i.e. adipokines, gastrointestinal hormones and cytokines levels. Aripiprazole did not influence body weight but it induced alterations in neurohumoral regulations. Leptin and GLP-1 serum levels were significantly reduced, while ghrelin level was elevated. Furthermore aripiprazole decreased serum levels of pro-inflammatory cytokines. Our data indicate dysregulation of adipokines and gastrointestinal hormones present after chronic treatment with aripiprazole which is considered metabolically neutral in the polyI:C model of schizophrenia.
ER -
HORSKÁ, Kateřina, Jana RUDÁ, Eva DRAŽANOVÁ, Michal KARPISEK, Regina DEMLOVÁ, Tomáš KAŠPÁREK a Hana KOTOLOVÁ. Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats. \textit{Neuropharmacology}. Oxford: Pergamon-Elsevier Science LTD, roč.~123, 1 September 2017, s.~148-158. ISSN~0028-3908. doi:10.1016/j.neuropharm.2017.06.003. 2017.
|
